Trial Profile
An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Breast cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- 07 Oct 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2018 Planned End Date changed from 1 Apr 2018 to 30 Apr 2019.
- 14 Dec 2017 Planned End Date changed from 1 Jan 2019 to 1 Apr 2018.